This phase II trial is evaluating the safety and effectiveness of using a targeted therapy (TTAC-0001) to treat patients with recurrent glioblastoma which progressed on therapy that included Bevacizumab.
This trial is treating patients with Glioblastoma.
This is a systemic treatment trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Multicenter, Open-Label, Phase Ⅱ Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients With Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy
Patients eligible to participate in this trial will receive a specified dose of TTAC-001 on Day 1 and Day 15 of a 28 day cycle.
Recruiting Hospitals Read More